Pathway to Progress presents independent economic modelling commissioned by Hepatitis Australia, with support from Gilead and GSK. It examines progress toward the National Hepatitis B and Hepatitis C targets and outlines the associated impacts for people, governments, and society.
The estimates combine economic modelling with lived experience insights to capture healthcare outcomes alongside broader effects on wellbeing, workforce participation, and human rights. The report shows that meeting the 2030 targets is cost‑effective, with clear benefits for equity, quality of life, and long‑term health system sustainability.
